Dabrafenib/trametinibPyrexia and basal cell carcinoma: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1846卷 / 1期

关键词：

D O I：

10.1007/s40278-021-92348-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：100 / 100

相关论文

共 50 条

[21] Vulvar Basal Cell Carcinoma: Four Case Reports With Immunohistochemical Study
Garcia-de-la-Fuente, M. A. Reyes
Santacana, Maria
Vilardell, Felip
Pujol, R. M.
Gari, Eloi
Casanova, J. M.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2017, 21 (05) : 457 - 459
[22] VismodegibDevelopment of primary and acquired resistance in basal cell carcinoma and disease progression: 2 case reports
Reactions Weekly, 2015, 1539 (1) : 290 - 290
[23] Dabrafenib/vemurafenibNeutrophilic eccrine hidradenitis: 2 case reports
Reactions Weekly, 2017, 1659 (1) : 86 - 86
[24] Dabrafenib/doxorubicin/pembrolizumabOdynophagia and diarrhoea: 2 case reports
Reactions Weekly, 2017, 1647 (1) : 103 - 103
[25] Dabrafenib/trametinibUveitis and ventricular dysfunction: 2 case reports
Reactions Weekly, 2017, 1668 (1) : 136 - 136
[26] Adalimumab/infliximab/purinesSquamous cell carcinoma, basal cell carcinoma and malignant melanoma: 3 case reports
Reactions Weekly, 2021, 1847 (1) : 22 - 22
[27] Cetuximab/dabrafenib/trametinibDrug resistance: 2 case reports
Reactions Weekly, 2020, 1823 (1) : 118 - 118
[28] Dabrafenib/vemurafenibNeutrophilic eccrine hidradenitis: 2 case reports
Reactions Weekly, 2017, 1662 (1) : 126 - 126
[29] Dabrafenib/ipilimumab/trametinibVarious toxicities: 2 case reports
Reactions Weekly, 2019, 1783 (1) : 99 - 99
[30] Dabrafenib/necitumumab/trametinibAcute pancreatitis: 2 case reports
Reactions Weekly, 2025, 2043 (1) : 125 - 125

← 1 2 3 4 5 →